

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
9 October 2003 (09.10.2003)

PCT

(10) International Publication Number
WO 2003/083135 A3

(51) International Patent Classification⁷: **C12Q 1/68**,
G01N 33/74, A61K 38/17

(21) International Application Number:
PCT/EP2003/002962

(22) International Filing Date: 21 March 2003 (21.03.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02007270.8 2 April 2002 (02.04.2002) EP

(71) Applicant (for all designated States except US): **BAYER
HEALTHCARE AG** [DE/DE]; 51368 Leverkusen (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GOLZ, Ste-
fan** [DE/DE]; Bückmannsmühle 46, 45326 Essen (DE).
BRÜGGEMEIER, Ulf [DE/DE]; Leysiefen 20, 42799 Le-
ichlingen (DE). **WEINGÄRTNER, Bernhard** [DE/DE];
Birkenweg 4, 42489 Wülfrath (DE).

(74) Common Representative: **BAYER HEALTHCARE
AG**; 51368 Leverkusen (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES,
FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG,
MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU,
SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG,
UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,
GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR),
OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG)

Published:

— with international search report
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
8 April 2004

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: **DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH NEUROPEPTIDE FF RECEPTOR 2
(NPFF2)**

(57) Abstract: The invention provides a human NPFF2 which is associated with the hematological diseases, cardiovascular dis-
eases, disorders of the peripheral and central nervous system, respiratory diseases like COPD and asthma, and genito-urological
disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of hemato-
logical diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, respiratory diseases like COPD and
asthma, and genito-urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity
of NPFF2 as well as pharmaceutical compositions comprising such compounds.



WO 2003/083135 A3

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 03/02962

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12Q1/68 G01N33/74 A61K38/17		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K C12Q G01N		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the International search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01/057188 A (HYSEQ INC ;LIU CHENGHUA (US); TANG Y TOM (US); DRMANAC RADOJE T (U) 9 August 2001 (2001-08-09) paragraph [04.8] - paragraph [4.20] -----	1-26
X	LECRON J-C ET AL: "Modulation of human lymphocyte proliferation by FLFQPQRFamide, a FMRFamide-like peptide with anti-opiate properties" JOURNAL OF NEUROIMMUNOLOGY 1992 NETHERLANDS, vol. 38, no. 1-2, 1992, pages 1-8, XP008024132 ISSN: 0165-5728 the whole document ----- <div style="text-align: center;">-/--</div>	1-26
<div style="display: flex; justify-content: space-between;"> <input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex. </div>		
<div style="display: flex;"> <div style="flex: 1;"> <p>* Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the International filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the International filing date but later than the priority date claimed</p> </div> <div style="flex: 1;"> <p>"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
Date of the actual completion of the International search <div style="text-align: center; font-weight: bold;">11 November 2003</div>		Date of mailing of the International search report <div style="text-align: center; font-weight: bold;">28. 01. 2004</div>
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl Fax: (+31-70) 340-3018		Authorized officer <div style="text-align: center; font-weight: bold;">Schalich, J</div>

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 03/02962

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 262 246 B1 (GERALD CHRISTOPHE P G ET AL) 17 July 2001 (2001-07-17) column 24 - column 30 column 38 - column 44 table 4 -----	1-26
X	KOTANI MASATO ET AL: "Functional characterization of a human receptor for neuropeptide FF and related peptides" BRITISH JOURNAL OF PHARMACOLOGY, vol. 133, no. 1, May 2001 (2001-05), pages 138-144, XP002260956 ISSN: 0007-1188 the whole document -----	1-17

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 03/02962

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: -
because they relate to subject matter not required to be searched by this Authority, namely:
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by surgery : claims 2-3
Rule 39.1(iv) PCT - Diagnostic method practised on the
2. ☒ Claims Nos.: -
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additio

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-26 (partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Claims Nos.: -

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by surgery : claims 2-3

Rule 39.1(iv) PCT - Diagnostic method practised on the human or animal body : claim 12

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy: claim 26

Continuation of Box I.2

Claims Nos.: -

Present claims 1-26 relate to diseases defined by reference to a characteristic or property only, namely to involve the haematological system. Present claims 19, 20 and 24-26 furthermore relate to compounds defined by reference to a desired characteristic or property, namely to bind to or modulate the activity of the receptor for neuropeptide FF 2 (NPFF2 receptor).

The claims cover all diseases and compounds having said characteristics or properties, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a very limited number of such diseases and compounds. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the diseases and compounds by reference to a result to be achieved.

The search was therefore restricted to the following subject-matter:

haematological diseases referred to in claims 1-26: leukemias, lymphomas, myelomas, anaemias, haemorrhagic, eosinophilic and spleen disorders, leukopenias and plasma cell dyscrasias as defined on p 57 to 58.

compositions referred to in claims 19, 20 and 24-26: antibodies, ribozymes and antisense polynucleotides

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-26 (in part)

Therapeutic and diagnostic use of NPFF2 receptor for
haematological diseases

2. claims: 1-26 (in part)

Therapeutic and diagnostic use of NPFF2 receptor for
cardiovascular diseases

3. claims: 1-26 (in part)

Therapeutic and diagnostic use of NPFF2 receptor for
disorders of the peripheral nervous system

4. claims: 1-26 (in part)

Therapeutic and diagnostic use of NPFF2 receptor for
disorders of the central nervous system

5. claims: 1-26 (in part)

Therapeutic and diagnostic use of NPFF2 receptor for
respiratory diseases

6. claims: 1-26 (in part)

Therapeutic and diagnostic use of NPFF2 receptor for
genito-urinary diseases

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/02962

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0157188	A	09-08-2001	AU 2591801 A	31-07-2001
			AU 3128801 A	14-08-2001
			AU 3297101 A	07-08-2001
			AU 3300301 A	07-08-2001
			AU 3329301 A	14-08-2001
			AU 3484701 A	14-08-2001
			AU 3484801 A	14-08-2001
			AU 3486501 A	14-08-2001
			AU 3494401 A	14-08-2001
			AU 3665801 A	14-08-2001
			AU 3666001 A	14-08-2001
			AU 3666301 A	14-08-2001
			AU 3672101 A	14-08-2001
			AU 4314201 A	14-08-2001
			CA 2398251 A1	02-08-2001
			CA 2399644 A1	09-08-2001
			CA 2399649 A1	09-08-2001
			CA 2399652 A1	09-08-2001
			CA 2399672 A1	09-08-2001
			CA 2399681 A1	09-08-2001
			CA 2399686 A1	09-08-2001
			CA 2399776 A1	09-08-2001
			EP 1261735 A2	04-12-2002
			EP 1254265 A1	06-11-2002
			EP 1254266 A1	06-11-2002
			EP 1254268 A1	06-11-2002
			EP 1254269 A1	06-11-2002
			EP 1254270 A1	06-11-2002
			JP 2003521251 T	15-07-2003
			WO 0153326 A1	26-07-2001
			WO 0155334 A2	02-08-2001
			WO 0155335 A2	02-08-2001
			WO 0157255 A1	09-08-2001
			WO 0157260 A1	09-08-2001
			WO 0157175 A2	09-08-2001
			WO 0157261 A1	09-08-2001
			WO 0157262 A1	09-08-2001
			WO 0157187 A2	09-08-2001
			WO 0157265 A1	09-08-2001
			WO 0157188 A2	09-08-2001
			WO 0157266 A1	09-08-2001
			WO 0157267 A1	09-08-2001
			WO 0157190 A2	09-08-2001
			US 2003100746 A1	29-05-2003
			US 2003138804 A1	24-07-2003
			US 2003165921 A1	04-09-2003
			US 2003158400 A1	21-08-2003
			US 2002128187 A1	12-09-2002
			US 2003180722 A1	25-09-2003
			US 2002137044 A1	26-09-2002
US 6262246	B1	17-07-2001	AU 6164999 A	17-04-2000
			CA 2311462 A1	06-04-2000
			EP 1032423 A1	06-09-2000
			JP 2002525095 T	13-08-2002
			WO 0018438 A1	06-04-2000
			US 2002198367 A1	26-12-2002